AVEO PHARMACEUTICALS, INC.

AVEO PHARMACEUTICALS, INC. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2001-01-01
Employees
115
Market Cap
-
Website
http://www.aveooncology.com

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

First Posted Date
2023-10-03
Last Posted Date
2024-12-18
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Target Recruit Count
410
Registration Number
NCT06064877
Locations
🇺🇸

University of California Los Angeles, Westwood, California, United States

🇺🇸

MaineHealth Institute for Research, South Portland, Maine, United States

🇺🇸

Manhattan Eye, Ear & Throat Hospital, New York, New York, United States

and more 99 locations

A Dose Escalation Study of AV-380 in Metastatic Cancer Patients with Cachexia

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-05-19
Last Posted Date
2024-11-18
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Target Recruit Count
30
Registration Number
NCT05865535
Locations
🇺🇸

Advent Health Orlando Hospital, Orlando, Florida, United States

🇺🇸

Piedmont Cancer Institute, Stockbridge, Georgia, United States

🇺🇸

New York Cancer And Blood Specialists, Riverhead, New York, United States

and more 3 locations

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2021-08-03
Last Posted Date
2024-10-24
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Target Recruit Count
343
Registration Number
NCT04987203
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center - Monmouth - Oncology, Middletown, New Jersey, United States

🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

Chao Family Comprehensive Cancer Center, UC Irvine, Irvine, California, United States

and more 135 locations

A Phase 1 Study of AV-380 in Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2021-03-25
Last Posted Date
2023-06-12
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Target Recruit Count
51
Registration Number
NCT04815551
Locations
🇺🇸

Biotrial Inc., Newark, New Jersey, United States

A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia

First Posted Date
2019-09-24
Last Posted Date
2020-03-31
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Registration Number
NCT04100330

A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2019-05-31
Last Posted Date
2023-07-12
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Target Recruit Count
27
Registration Number
NCT03970616
Locations
🇺🇸

University of California - Irvine, Orange, California, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

City of Hope, Duarte, California, United States

and more 7 locations

Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC

Phase 1
Completed
Conditions
Interventions
First Posted Date
2017-05-02
Last Posted Date
2021-12-06
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Target Recruit Count
28
Registration Number
NCT03136627
Locations
🇫🇷

Bordeaux Hospital University Center (CHU), Bordeaux, France

🇫🇷

Center Léon Bérard, Lyon, France

🇫🇷

Centre Paul Strauss, Strasbourg, France

and more 1 locations

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

First Posted Date
2015-12-11
Last Posted Date
2023-07-18
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Target Recruit Count
350
Registration Number
NCT02627963
Locations
🇨🇦

Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada

🇺🇸

New York Oncology Hematology, PC, Albany, New York, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 182 locations

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

First Posted Date
2014-12-17
Last Posted Date
2020-10-22
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Target Recruit Count
10
Registration Number
NCT02318368
Locations
🇦🇺

Frankston Hospital, Frankston, Victoria, Australia

🇮🇹

IRCCS Ospedale S.Raffaele, Milano, Italy

🇮🇹

IRCCS Istituto Clinico Humanitas, Rozzano MI, Italy

and more 44 locations

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

First Posted Date
2014-03-18
Last Posted Date
2015-07-29
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Registration Number
NCT02090127
Locations
🇺🇸

START, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath